Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q4 2023 call → NOThe question asks whether management conveys that the company is running on a different basis than its reported results and reputation were built on, with both halves: (1) a change of basis already real, and (2) management says the record and perception lag the change. Let me examine the transcript carefully. The company is Palatin Technologies. They have Vyleesi (commercial product for HSDD), and they have pipeline programs: PL9643 for dry eye disease (Phase III fully enrolled), PL8177 for ulcerative colitis (Phase II), PL9588 for glaucoma (preclinical), and a new combination for erectile dysfunction. Key statements from management: 1. On Vyleesi: "The goal of the Vyleesi program is to demonstrate commercial product value in the marketplace. With six consecutive quarters of double-digit growth... I think we are doing that. But the objective is to re-license the U.S. rights to a committed women's health care company, and that process is advancing." 2. On the business model: Steve Wills says "we're not losing any money. In fact, we're making money on Vyleesi. We have a very limited infrastructure. Our plan is the targeted profitable growth, and we're doing that." 3. On the pipeline: They have multiple clinical programs, data coming from 3 clinical trials, initiation of 2 new clinical programs. 4. On the ED combination: "we have developed a co-formulation of our melanocortin receptor-4 agonist bremelanotide with a phosphodiesterase-5 inhibitor as a treatment for men with erectile dysfunction that have failed current PDE-5 inhibitor therapy." 5. On the company's evolution: Carl Spana says "we have continued to successfully execute on our strategy to develop novel therapeutics based on activating the melanocortin system." Now, does management describe the company as having crossed into being a different kind of business? The company historically was a development-stage biotech. Now it has a commercial product (Vyleesi) that is generating revenue and making money. But is that a "change of basis"? The company still has the same core strategy - melanocortin system. Vyleesi is a melanocortin agonist. Let me look for specific language about the company being different now. Steve Wills: "we're not losing any money. In fact, we're making money on Vyleesi. We have a very limited infrastructure.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...